Emgality ® ▼ (galcanezumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

Were hypersensitivity events / allergic reactions observed in patients treated with Emgality® ▼ (galcanezumab)?

Serious hypersensitivity reactions, including anaphylaxis, angioedema and urticaria, have been reported. The reactions may occur within 1 day or with a delayed onset ranging from more than 1 day to 4 weeks after administration.

UK_cFAQ_GLC111_Z1_HYPERSENSITIVITY EVENTS_MIGRAINE
UK_cFAQ_GLC111_Z1_HYPERSENSITIVITY EVENTS_MIGRAINE
en-GB

Hypersensitivity Events from Emgality Summary of Product  Characteristics

Galcanezumab is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients.1

Serious hypersensitivity

Serious hypersensitivity reactions including cases of anaphylaxis, angioedema and urticaria have been reported. 1

Serious hypersensitivity reactions may occur within 1 day after galcanezumab administration, however cases with a delayed onset (ranging from more than 1 day to 4 weeks after administration) have also been reported. In some cases, hypersensitivity reactions had a prolonged duration.1

If a serious hypersensitivity reaction occurs, administration of galcanezumab should be discontinued immediately and appropriate therapy initiated.  Patients should be informed on the possibility of a delayed onset hypersensitivity reaction and instructed to contact their physician.1

Relevant adverse reactions listed in the SmPC

The system organ class "Immune system disorders" lists anaphylaxis and angioedema that have been reported in clinical studies and post-marketing reports (Frequency estimand rare, ≥ 1/10,000 to < 1/1,000).1

Furthermore both, pruritus and rash, are a common adverse reaction of galcanezumab (frequency estimand common, ≥ 1/100 to < 1/10) . Pruritus was reported by 0.7 % and 1.2 % of patients with 120 mg and 240 mg galcanezumab in migraine clinical trials, respectively.1

Urticaria has been reported by 0.3 % and 0.1 % of patients with 120 mg and 240 mg galcanezumab in migraine clinical trials. While urticaria is uncommon, serious cases have been reported in galcanezumab clinical studies.1

Read the full Summary of Product Characteristics for Emgality for full prescribing information and further details about adverse drug reactions reported in galcanezumab clinical trials and post-marketing reports.

Hypersensitivity events in the phase 3 migraine preventive studies

Galcanezumab has been studied in migraine prevention studies.2-6 A brief overview of the phase 3 migraine prevention is provided in the Summary of Study Design in the Migraine Prevention Studies. Hypersensitivity events from the migraine prevention studies are summarized separately below.

Characterization of Hypersensitivity Events

Most events

  • were nonserious
  • were mild or moderate in severity, and
  • did not lead to discontinuation of galcanezumab.7,8

The time course of hypersensitivity events did not appear different in the galcanezumab-treated patients compared to placebo and there was no trend for an increase in hypersensitivity events with increasing treatment duration up to 12 months.7

Incidence of Hypersensitivity Events

There were no anaphylaxis events reported in the phase 3 migraine prevention studies.7,8

Hypersensitivity events occurred more frequently in patients treated with galcanezumab than with placebo in

When considering all galcanezumab-treated patients during all treatment phases, the frequency of hypersensitivity events was comparable to the frequencies observed during the double-blind treatment phase.7

Overview of Likely Hypersensitivity Events After Medical Review: Phase 3 Double-Blind, Placebo-Controlled Migraine Prevention Studies (EVOLVE-1, EVOLVE-2, REGAIN)7

Preferred Terma


PBO
N=1451
n (%)
GMB 120 mg
N=705
n (%)
GMB 240 mg
N=730
n (%)

Immediate (on day of drug administration)

Dermatitis contact

1 (0.07)

0 (0.00)

0 (0.00)

Injection site hypersensitivity

0 (0.00)

1 (0.14)

1 (0.14)

Injection site rash

2 (0.14)

3 (0.43)

3 (0.41)

Injection site urticaria

1 (0.07)

1 (0.14)

1 (0.14)

Pruritus allergic

0 (0.00)

1 (0.14)

0 (0.00)

Rash

1 (0.07)

0 (0.00)

1 (0.14)

Urticaria

0 (0.00)

2 (0.28)b,c

0 (0.00)

Nonimmediate (beyond day of drug administration)

Bronchospasm

1 (0.07)

0 (0.00)

0 (0.00)

Conjunctivitis allergic

1 (0.07)

0 (0.00)

0 (0.00)

Dermatitis allergic

0 (0.00)

3 (0.43)b

0 (0.00)

Dermatitis atopic

1 (0.07)

0 (0.00)

1 (0.14)

Dermatitis contact

3 (0.21)

3 (0.43)

4 (0.55)

Drug hypersensitivity

1 (0.07)

0 (0.00)

0 (0.00)

Eczema

3 (0.21)

1 (0.14)

2 (0.27)

Eye allergy

0 (0.00)

1 (0.14)

0 (0.00)

Hypersensitivity

0 (0.00)

3 (0.43)b

2 (0.27)b

Injection site hypersensitivity

0 (0.00)

0 (0.00)

2 (0.27)b

Injection site rash

0 (0.00)

4 (0.57)b

2 (0.27)b

Rash

14 (0.96)

5 (0.71)

6 (0.82)

Rash erythematous

1 (0.07)

0 (0.00)

1 (0.14)

Rash generalized

1 (0.07)

1 (0.14)

1 (0.14)

Rash maculopapular

1 (0.07)

1 (0.14)

0 (0.00)

Rash papulosquamous

0 (0.00)

1 (0.14)

1 (0.14)

Rash pruritic

0 (0.00)

2 (0.28)b

1 (0.14)

Rhinitis allergic

3 (0.21)

3 (0.43)

4 (0.55)

Urticaria

5 (0.34)

1 (0.14)

1 (0.14)

Abbreviations: GMB = galcanezumab; MedDRA = Medical Dictionary for Regulatory Activities; PBO = placebo.

aIdentified by a standardized MedDRA query (version 19.1) narrow term search.

bp≤.05 vs placebo.

cCases reported as nonserious urticaria.

The frequency of treatment-emergent likely hypersensitivity events was not significantly different between the galcanezumab and placebo treatment groups during double-blind treatment in the CONQUER study and  during open-label treatment in the 12-month open-label safety study: Overview of Likely Hypersensitivity Events After Medical Review: Double-Blind Treatment Phase of the CONQUER Study and Overview of Likely Hypersensitivity Events After Medical Review: Open-Label Safety Study.5 

Overview of Likely Hypersensitivity Events After Medical Review: Double-Blind Treatment Phase of the CONQUER Study5,7

Preferred Terma

PBO
N=230
n (%)

GMB 120 mg
N=232
n (%)

Within 24 hours

Rash

1 (0.43)

0 (0.00)

Urticaria

1 (0.43)

0 (0.00)

After 24 hours

Eczema

1 (0.43)

0 (0.00)

Injection site hypersensitivity

0 (0.00)

1 (0.43)

Rash

2 (0.87)

3 (1.29)

Rash generalized

0 (0.00)

1 (0.43)

Rash macular

1 (0.43)

0 (0.00)

Rhinitis allergic

2 (0.87)

1 (0.43)

Toxic skin eruption

0 (0.00)

1 (0.43)

Abbreviations: GMB = galcanezumab; MedDRA = Medical Dictionary for Regulatory Activities; PBO = placebo.

aIdentified by a standardized MedDRA query (version 22.0) narrow term search.

The incidence of treatment-emergent adverse events related to hypersensitivity events was similar between galcanezumab dose groups during open-label treatment in the 12-month open-label safety study: Overview of Likely Hypersensitivity Events After Medical Review: Open-Label Safety Study.7

Overview of Likely Hypersensitivity Events After Medical Reviewa: Open-Label Safety Study7

Preferred Termb

GMB 120 mg
N=129
n (%)

GMB 240 mg
N=141
n (%)

Dermatitis allergic

2 (1.55)

0 (0.00)

Hypersensitivity

1 (0.78)

0 (0.00)

Injection site rash

1 (0.78)

1 (0.71)

Injection site urticaria

1 (0.78)

0 (0.00)

Pruritus allergic

0 (0.00)

1 (0.71)

Rash

1 (0.78)

1 (0.71)

Rash generalized

0 (0.00)

1 (0.71)

Rash maculo-papular

0 (0.00)

1 (0.71)

Rhinitis allergic

1 (0.78)

1 (0.71)

Skin reaction

0 (0.00)

1 (0.71)

Urticaria

1 (0.78)

1 (0.71)

Abbreviations: GMB = galcanezumab; MedDRA = Medical Dictionary for Regulatory Activities.

aOf the 10 treatment-emergent hypersensitivity events where reaction timing was available, events that occurred on the day of injection included rash (n=2), injection site urticaria (n=1), and pruritus (n=1). All other events occurred after the day of injection.

bIdentified by a standardized MedDRA query (version 19.1) narrow term search.

Please note that the results of a maintenance dose of 240 mg galcanezumab once monthly are also included in this response. Even though this dose has been tested in pivotal studies, it has not been approved and therefore is not recommended.

Serious Adverse Events

No patient in any treatment group had an immediate or a nonimmediate hypersensitivity-related serious adverse event (SAE) during the double-blind treatment period in the EVOLVE-1, EVOLVE-2, REGAIN, and CONQUER studies.5,7

Two serious cases of urticaria occurred during the open-label and posttreatment phase of REGAIN. Neither patient

  • reported other associated symptoms, or
  • was positive for treatment-emergent antidrug antibodies.8

Hypersensitivity Related Treatment-Emergent Adverse Events Leading to Study Discontinuations

In the EVOLVE-1, EVOLVE-2, and REGAIN studies, no event leading to discontinuation was reported by >1 patient, and all events resolved with supportive care. Patients discontinued because of:

  • generalized rash and pruritic rash in the galcanezumab 120-mg group, and
  • dyspnea and hypersensitivity in the galcanezumab 240-mg group.8

Discontinuations due to a hypersensitivity event during CONQUER were reported by

  • 1 galcanezumab-treated patient during double-blind treatment (rash generalized),5 and
  • 1 galcanezumab-treated patient during open-label treatment (upper body rash).7

One patient discontinued due to a hypersensitivity event of rash in the open-label safety study.6

Postmarketing Spontaneous Reports

Based on postmarketing spontaneous reports from the Eli Lilly and Company spontaneous adverse event (AE) database received through March 27, 2022,

  • angioedema and anaphylactic reaction were very rarely reported (<0.01%), and
  • rash was rarely reported (≥0.01% and <0.1%).7

Through March 27, 2022, there were reported postmarketing cases consistent with hypersensitivity in the Eli Lilly and Company spontaneous adverse event (AE) database. There have been no fatal cases of serious hypersensitivity.7

Postmarketing cases consistent with anaphylaxis, angioedema, and rash through March 27, 2019 are summarized in Galcanezumab Postmarketing Cases Consistent With Anaphylaxis, Angioedema, and Rash (Through March 27, 2019). This specific information is not available from the reporting period through March 27, 2022.

Galcanezumab Postmarketing Cases Consistent With Anaphylaxis, Angioedema, and Rash (Through March 27, 2019)7

 

Timing

Details

Anaphylaxis

The timing of the event was immediatea in a majority of cases.

In a majority of cases, patients went to the emergency room or urgent care, or were hospitalized.

In several cases, the patient had a history of allergies.

Angioedema

The timing of the event was nonimmediate,b in a majority of cases.


In several cases, the time to onset was unknown.

The majority of cases were nonserious and several cases were serious (throat swelling and facial swelling).

Some cases were confounded by underlying inflammatory/infectious conditions or a possible insect bite.

Rash

The information on timing was not reported or undetermined in a majority of cases.


In some cases, the rash was reported to occur on the same day of either the initial or loading dose (minutes or hours after injections) or during the following days.


In a few other cases, the rash occurred at the time of the subsequent monthly doses.

All rashes were reported as nonserious.


Most events were reported simply as rash, but generalized, pruritic, erythematous, macular, vesicular, and papular rashes were also reported in a few cases.

aImmediate = occurring within 24 hours of galcanezumab administration.

bNonimmediate = occurring greater than 24 hours after galcanezumab administration.

Postmarketing data do not necessarily represent the rate of occurrence of an AE in a treated population, but they represent a reporting rate of a particular AE to the company. Spontaneous reporting of AEs can be highly variable and is not appropriately controlled clinical information on which to base an assessment of whether a particular drug product is the causal agent of an event.9

Spontaneous reporting has limited use due to

  • lack of control population
  • under-reporting or reporting bias, and
  • missing or incomplete information regarding medical history or concomitant medications.9

References

1Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. http://dx.doi.org/10.1001/jamaneurol.2018.1212

3Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. http://dx.doi.org/10.1177/0333102418779543

4Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. http://dx.doi.org/10.1212/WNL.0000000000006640

5Mulleners WM, Kim BK, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814-825. http://dx.doi.org/10.1016/S1474-4422(20)30279-9

6Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188. http://dx.doi.org/10.1186/s12883-018-1193-2

7Data on file, Eli Lilly and Company and/or one of its subsidiaries.

8Bangs ME, Kudrow D, Wang S, et al. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020;20(1):25. https://doi.org/10.1186/s12883-020-1609-7

9Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20(suppl 3):C40-C44. http://dx.doi.org/10.1016/S0149-2918(98)80007-6

10Levin M, Silberstein SD, Gilbert R, et al. Basic considerations for the use of monoclonal antibodies in migraine. Headache. 2018;58(10):1689-1696. http://dx.doi.org/10.1111/head.13439

Appendix

Background information

Therapeutic proteins, including monoclonal antibodies, have been associated with hypersensitivity events.10 Therefore, these events were closely monitored in the phase 3 studies, in order to understand the potential for hypersensitivity with the use of galcanezumab.7

Galcanezumab is a self-administered medication. The package labeling contains no requirements to monitor the patient after administration for hypersensitivity reactions.7

It is not known if previous hypersensitivity to another biological product constitutes a risk factor for treatment with galcanezumab since galcanezumab studies excluded patients with a history of hypersensitivity to

  • monoclonal antibodies, or 
  • therapeutic proteins.7

Hypersensitivity is neither predictable nor preventable. No correlation with antibody formation has been observed.7

Overview of Phase 3 Double-Blind, Placebo-Controlled Migraine Prevention Studies

Galcanezumab has been studied in phase 3 randomized, double-blind, placebo-controlled studies in adult patients for the prevention of

  • episodic migraine (EVOLVE-1 and EVOLVE-2)2,3
  • chronic migraine (REGAIN),4 and
  • episodic or chronic migraine that has not benefited from 2 to 4 previous migraine prevention medication categories (CONQUER).5

Galcanezumab has also been studied in a phase 3, open-label, 12-month safety study for the prevention of episodic or chronic migraine.6

The galcanezumab doses used and duration of the migraine prevention studies are summarized in Summary of Study Design in the Migraine Prevention Studies.

Summary of Study Design in the Migraine Prevention Studiesa

Study Name 

Treatments

Study Duration

EVOLVE-12

EVOLVE-23

PBO, GMB 120 mg monthly,b
or
240 mg SQ monthly

6-month double-blind

REGAIN4

PBO, GMB 120 mg monthly,b
or
240 mg SQ monthly

3-month double-blind,
with optional 9-month open-label extension

CONQUER5

PBO or GMB 120 mg SQ monthlyb

3-month double-blind, 
with optional 3-month open-label extension

CGAJ6

 GMB 120 mg b
or
240 mg SQ monthly

12-month open-label

Abbreviations: GMB = galcanezumab; PBO = placebo; SQ = subcutaneous.

aWith the exception of study CGAJ, all studies were randomized, double-blind, and placebo-controlled.

bThe initial dose was administered as a 240-mg loading dose, followed by subsequent monthly doses of 120 mg.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: 18 July 2022


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request